Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ILMN

Illumina Inc

Feb 06 • 04:00PM ET

119.72

-13.89 -10.40 %

Healthcare • Diagnostics & Research • USA • NASD

Feb 06, 8:30 PMDisappointing 2026 revenue guidance sparked a sharp sell-off despite Q4 earnings beat.

Peers: PACB VRTX TXG QGEN GH BIO MYGN IONS TWST OMIC

| Held by: IJH VTI VB VBR VXF XMHQ MDY IBB SPMD ARKK

Index	-	P/E	21.95	EPS (ttm)	5.45	Insider Own	2.81%	Shs Outstand	152.80M	Perf Week	-17.33%
Market Cap	18.29B	Forward P/E	20.53	EPS next Y	5.83	Insider Trans	-0.01%	Shs Float	148.51M	Perf Month	-20.26%
Enterprise Value	19.14B	PEG	1.79	EPS next Q	1.07	Inst Own	104.70%	Short Float	4.35%	Perf Quarter	-2.22%
Income	850.00M	P/S	4.22	EPS this Y	5.72%	Inst Trans	1.49%	Short Ratio	3.51	Perf Half Y	25.36%
Sales	4.34B	P/B	7.69	EPS next Y	13.98%	ROA	13.13%	Short Interest	6.46M	Perf YTD	-8.72%
Book/sh	15.56	P/C	11.20	EPS next 5Y	11.44%	ROE	33.36%	52W High	155.53 -23.02%	Perf Year	-3.98%
Cash/sh	10.69	P/FCF	18.29	EPS past 3/5Y	- 4.22%	ROIC	18.09%	52W Low	68.70 74.26%	Perf 3Y	-43.10%
Dividend Est.	-	EV/EBITDA	16.44	Sales past 3/5Y	-1.78% 6.04%	Gross Margin	67.07%	Volatility	5.16% 4.16%	Perf 5Y	-72.22%
Dividend TTM	-	EV/Sales	4.41	EPS Y/Y TTM	171.36%	Oper. Margin	20.58%	ATR (14)	6.06	Perf 10Y	-22.01%
Dividend Ex-Date	-	Quick Ratio	1.72	Sales Y/Y TTM	-0.73%	Profit Margin	19.59%	RSI (14)	27.94	Recom	2.52
Dividend Gr. 3/5Y	- -	Current Ratio	2.08	EPS Q/Q	84.80%	SMA20	-16.92%	Beta	1.47	Target Price	135.06
Payout	0.00%	Debt/Eq	0.91	Sales Q/Q	4.98%	SMA50	-13.27%	Rel Volume	2.47	Prev Close	133.61
Employees	10370	LT Debt/Eq	0.73	Earnings	Feb 05 AMC	SMA200	12.02%	Avg Volume	1.84M	Price	119.72
IPO	Jul 28, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.70% 3.60%	Trades		Volume	4,451,159	Change	-10.40%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-12-25	Downgrade	Daiwa Securities	Outperform → Neutral	$94
Jul-11-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$125
Mar-04-25	Reiterated	Citigroup	Neutral	$130 → $90
Feb-28-25	Downgrade	HSBC Securities	Buy → Hold	$100
Feb-10-25	Downgrade	Barclays	Equal Weight → Underweight	$130 → $100
Feb-07-25	Downgrade	TD Cowen	Buy → Hold	$177 → $140
Dec-11-24	Downgrade	Citigroup	Buy → Neutral	$190 → $165
Nov-12-24	Resumed	Morgan Stanley	Equal-Weight	$156
Oct-17-24	Upgrade	HSBC Securities	Hold → Buy	$180
Aug-28-24	Upgrade	Argus	Hold → Buy
Aug-16-24	Upgrade	Daiwa Securities	Neutral → Buy	$120 → $154
Aug-14-24	Upgrade	TD Cowen	Hold → Buy	$126 → $144
Aug-14-24	Upgrade	Barclays	Underweight → Equal Weight	$125
Jul-10-24	Upgrade	Citigroup	Neutral → Buy	$140
Jun-03-24	Resumed	Jefferies	Hold	$115
Jan-16-24	Downgrade	HSBC Securities	Buy → Hold
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$144
Dec-18-23	Upgrade	Scotiabank	Sector Perform → Sector Outperform	$185
Dec-15-23	Upgrade	Bernstein	Underperform → Mkt Perform
Dec-14-23	Initiated	Stephens	Overweight	$170

Show Previous Ratings

Feb-06-26 01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga) -10.40%
03:48AM	Analyst Report: Illumina, Inc. (Morningstar Research)
12:36AM	ILMN Q4 Deep Dive: Clinical Consumables Growth, Multiomics Expansion, and Margin Momentum (StockStory)
12:05AM	Illumina Inc (ILMN) Q4 2025 Earnings Call Highlights: Strong Clinical Growth Amidst Research ... (GuruFocus.com)
Feb-05-26 08:58PM	Illumina Q4 Earnings Call Highlights (MarketBeat)
07:00PM	Loading…
07:00PM	Illumina (ILMN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:00PM	Illumina (ILMN) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:59PM	Illumina: Q4 Earnings Snapshot (Associated Press Finance)
04:17PM	Illumina (NASDAQ:ILMN) Reports Bullish Q4 CY2025 (StockStory)
04:06PM	Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 (PR Newswire)
Feb-04-26 09:15AM	Insights Into Illumina (ILMN) Q4: Wall Street Projections for Key Metrics (Zacks)
Feb-03-26 10:18PM	Illumina (ILMN) Reports Q4: Everything You Need To Know Ahead Of Earnings (StockStory)
06:15PM	Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
09:15AM	Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo, supporting critical conservation genetics efforts globally (PR Newswire)
08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
09:37AM	Loading…
Feb-02-26 09:37AM	ILMN Q4 Earnings Preview: NovaSeq X Momentum Likely to Aid Performance (Zacks)
12:47AM	Grail files for FDA approval of multi-cancer early detection test (MedTech Dive)
Jan-30-26 10:00AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
09:05AM	Illumina completes acquisition of SomaLogic (PR Newswire)
Jan-29-26 10:00AM	Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jan-27-26 08:55AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Jan-24-26 12:01PM	The Most Expensive Question Investors Ask (Barchart)
Jan-23-26 11:40AM	REGN or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
Jan-21-26 10:31PM	Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest (StockStory)
04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-20-26 01:19PM	Illumina Gets Medicare Boost for Cancer Test, Shares Climb (Benzinga)
09:15AM	Illumina secures CMS reimbursement for TruSight Oncology Comprehensive, expanding access to precision oncology (PR Newswire)
04:58AM	Illumina Inc. (ILMN) Shares See Target Boost as Analysts See Potential 2026 Upside (Insider Monkey)
12:05AM	Cathie Wood's Ark Unleashes Cryptic ARKmoji Teasers To Showcase Its 'Big Ideas' For 2026: Can You Take A Guess At The Hidden Meaning? (Benzinga)
Jan-16-26 02:22AM	The clinical candidates pharma execs are tracking (Pharma Voice)
08:55AM	Loading…
Jan-15-26 08:55AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jan-13-26 04:58PM	Illumina CEO Sees Big Growth Opportunity in China (Bloomberg)
01:01PM	JPM26: Illumina debuts Billion Cell Atlas to drive AI-driven drug discovery (Pharmaceutical Technology)
12:37PM	Analyst Report: Illumina, Inc. (Morningstar Research)
09:15AM	Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery (PR Newswire)
09:00AM	Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 (PR Newswire)
07:30AM	TEM's Collab for Oncology Patient Population Is Gaining Attention (Zacks)
Jan-12-26 04:07PM	Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 (PR Newswire)
11:34AM	Nvidia, Eli Lilly announce $1 billion investment in AI drug discovery lab (Yahoo Finance)
08:09AM	Illumina's New Connected Multiomics Platform Set to Boost Its Stock (Zacks)
Jan-09-26 12:10PM	Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Jan-08-26 04:30PM	Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026 (Business Wire)
04:30PM	Illumina Appoints Dr. Eric Green as Chief Medical Officer (PR Newswire)
Jan-07-26 11:40AM	REGN vs. ILMN: Which Stock Is the Better Value Option? (Zacks)
07:33AM	TEM's Stable Solvency and Financial Strength Are Gaining Attention (Zacks)
Jan-06-26 07:48PM	Analyst Report: Illumina, Inc. (Morningstar Research)
11:40AM	REGN vs. ILMN: Which Stock Should Value Investors Buy Now? (Zacks)
09:15AM	Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis (PR Newswire)
07:06AM	Three Genomics Stocks Worth Tracking This Year (Zacks)
Jan-02-26 07:35AM	Is This the Right Time to Add PBH Stock to Your Portfolio? (Zacks)
Dec-31-25 09:50AM	Here's Why Illumina (ILMN) is a Strong Momentum Stock (Zacks)
01:30AM	It's Earnings Warning Season. How to Profit From Others' Misery. (Barrons.com)
Dec-30-25 08:06AM	Should Myriad Genetics Stock Stay in Your Portfolio Right Now? (Zacks)
07:32AM	Should You Continue to Hold EXAS Stock in Your Portfolio Now? (Zacks)
Dec-26-25 07:49AM	Should You Continue to Hold BRKR Stock in Your Portfolio? (Zacks)
07:18AM	How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up (Zacks)
07:17AM	Reasons to Retain Penumbra Stock in Your Portfolio for Now (Zacks)
Dec-24-25 08:36AM	Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now? (Zacks)
Dec-23-25 02:08PM	Is This the Right Time to Add Veracyte Stock to Your Portfolio? (Zacks)
02:08PM	Abbott Stock May Benefit Following Volt PFA's FDA Approval (Zacks)
Dec-22-25 07:49AM	TMO Stock May Benefit From PPD CorEvitas Alzheimer's Registry Launch (Zacks)
07:11AM	Illumina (ILMN) Surges 3.3%: Is This an Indication of Further Gains? (Zacks)
Dec-19-25 09:09AM	National Vision Stock Surges 154.6% in a Year: What's Driving it? (Zacks)
Dec-18-25 08:36AM	Should You Continue to Hold CRL Stock in Your Portfolio for Now? (Zacks)
07:45AM	Should Investors Hold Chemed Stock in Their Portfolio Now? (Zacks)
Dec-17-25 10:14AM	Can These 5 Relative Price Strength Stocks Lead in 2026? (Zacks)
07:58AM	How the OneStep Partnership Could Drive Growth for ZBH Stock (Zacks)
07:55AM	Should You Retain Teleflex Stock in Your Portfolio Now? (Zacks)
Dec-16-25 04:05PM	Illumina To Webcast Upcoming Investor Conference (PR Newswire)
07:58AM	Is Phibro Animal Health Stock a Smart Addition to Your Portfolio Now? (Zacks)
07:47AM	TMO Stock Set to Gain From the Expansion of Gibco Bacto Portfolio (Zacks)
Dec-15-25 09:12AM	CVS Stock Gains From Offering MMR Vaccine to South Carolina Residents (Zacks)
Dec-12-25 09:50AM	Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term (Zacks)
07:11AM	Is it Apt to Retain Haemonetics Stock in Your Portfolio Now? (Zacks)
Dec-11-25 09:15AM	Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually (PR Newswire)
08:09AM	Should You Continue to Hold EW Stock in Your Portfolio? (Zacks)
Dec-10-25 08:34AM	Is it Worth Retaining NEOG Stock in Your Portfolio for Now? (Zacks)
08:31AM	Phibro Animal Health Stock Climbs 59.6% YTD: What's Driving It? (Zacks)
Dec-09-25 07:28AM	ALGN Stock Rises on Thailand Launch of Invisalign With MAOB (Zacks)
07:27AM	Reasons to Hold Tandem Diabetes Stock in Your Portfolio for Now (Zacks)
07:26AM	RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort (Zacks)
04:49AM	Zacks.com featured highlights include Illumina, Commercial Metals and Newmont (Zacks)
Dec-08-25 10:15AM	Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook (Zacks)
09:45AM	Bet on These 3 Stocks With Upgraded Broker Ratings Amid Uncertainties (Zacks)
07:56AM	PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements (Zacks)
Dec-05-25 11:30AM	Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report? (Zacks)
08:48AM	MDT Stock Set to Benefit From the FDA Clearance of Hugo RAS System (Zacks)
Dec-04-25 11:30AM	Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? (Zacks)
07:20AM	New Strong Buy Stocks for December 4th (Zacks)
Dec-03-25 12:00PM	Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
Nov-20-25 04:15PM	Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth (Business Wire)
05:00AM	Roche inks deal for rights to Freenome cancer tests outside US (MedTech Dive)
Nov-19-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-18-25 11:01PM	3 Reasons to Sell ILMN and 1 Stock to Buy Instead (StockStory)
08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
Nov-12-25 12:00PM	Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study (PR Newswire)
Nov-11-25 04:05PM	Illumina To Webcast Upcoming Investor Conference (PR Newswire)
11:40AM	ALKS or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
Nov-10-25 01:31PM	Final Trades: Morgan Stanley, Cisco Systems, Illumina and FTAI Aviation (CNBC TV)

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Davies Scott M	Chief Legal Officer	Dec 12 '25	Sale	136.09	323	43,957	17,887	Dec 16 05:00 PM
SCOTT DAVIES	Officer	Dec 12 '25	Proposed Sale	136.09	323	43,957		Dec 12 04:09 PM
Wedel Christensen Jakob	SVP, Strategy/Corp Development	Dec 08 '25	Sale	129.27	549	70,969	10,952	Dec 09 04:15 PM
JAKOB WEDEL	Officer	Dec 08 '25	Proposed Sale	129.27	549	70,969		Dec 08 04:31 PM
ILLUMINA, INC.	10% Owner	Nov 17 '25	Sale	79.85	1,000,000	79,850,000	3,502,126	Nov 18 09:33 PM
SCOTT DAVIES	Officer	Nov 12 '25	Proposed Sale	122.79	323	39,661		Nov 12 04:05 PM
Gottlieb Scott	Director	Nov 03 '25	Buy	122.13	500	61,065	12,523	Nov 05 04:05 PM
Dhingra Ankur	SVP, Chief Financial Officer	May 12 '25	Buy	81.21	6,100	495,381	24,906	May 14 04:20 PM
Thaysen Jacob	Chief Executive Officer	May 12 '25	Buy	80.88	6,500	525,732	77,540	May 14 04:18 PM
Thaysen Jacob	Chief Executive Officer	May 13 '25	Buy	80.84	5,850	472,942	83,390	May 14 04:18 PM
JAKOB WEDEL CHRISTENSEN	Officer	May 06 '25	Proposed Sale	77.21	549	42,388		May 06 04:02 PM
ARNOLD FRANCES	Director	Feb 27 '25	Proposed Sale	93.48	120	11,218		Feb 27 11:07 AM
JAKOB WEDEL	Officer	Feb 18 '25	Proposed Sale	100.00	460	46,000		Feb 18 04:22 PM
PATRICIA L LECKMAN	Officer	Feb 18 '25	Proposed Sale	100.00	1,756	175,600		Feb 18 04:08 PM

Open in Screener

SMMT

Summit Therapeutics Inc

Feb 06 • 04:00PM ET

14.99

+1.14 8.23 %

Healthcare • Biotechnology • USA • NASD

SMMT Summit Therapeutics Inc daily Stock Chart

Peers: VRTX REGN GILD NBIX ALNY BIIB AMGN SRPT AKTX PRTA

| Held by: XBI VTI VB VBR VXF IWP IBB VHT IWF IWR

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	86.17%	Shs Outstand	744.44M	Perf Week	3.52%
Market Cap	11.16B	Forward P/E	-	EPS next Y	-0.90	Insider Trans	0.20%	Shs Float	102.98M	Perf Month	-21.15%
Enterprise Value	10.93B	PEG	-	EPS next Q	-0.09	Inst Own	13.83%	Short Float	36.12%	Perf Quarter	-17.04%
Income	-921.61M	P/S	-	EPS this Y	-233.75%	Inst Trans	2.77%	Short Ratio	13.90	Perf Half Y	-46.60%
Sales	0.00M	P/B	58.04	EPS next Y	13.33%	ROA	-241.08%	Short Interest	37.20M	Perf YTD	-14.29%
Book/sh	0.26	P/C	46.71	EPS next 5Y	-	ROE	-292.49%	52W High	36.91 -59.39%	Perf Year	-27.86%
Cash/sh	0.32	P/FCF	-	EPS past 3/5Y	31.56% -10.52%	ROIC	-472.69%	52W Low	13.83 8.39%	Perf 3Y	294.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.96% 6.11%	Perf 5Y	115.37%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-348.63%	Oper. Margin	-	ATR (14)	0.89	Perf 10Y	32.07%
Dividend Ex-Date	-	Quick Ratio	3.80	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.11	Recom	1.59
Dividend Gr. 3/5Y	- -	Current Ratio	3.80	EPS Q/Q	-302.84%	SMA20	-6.94%	Beta	-1.43	Target Price	32.43
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-12.66%	Rel Volume	1.01	Prev Close	13.85
Employees	159	LT Debt/Eq	0.01	Earnings	Oct 20 BMO	SMA200	-29.65%	Avg Volume	2.68M	Price	14.99
IPO	Mar 05, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-82.25% -	Trades		Volume	2,708,912	Change	8.23%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Upgrade	Barclays	Underweight → Equal Weight	$18
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Underweight	$13
Sep-04-25	Initiated	Guggenheim	Buy	$40
Aug-19-25	Initiated	Piper Sandler	Neutral	$21
Jul-01-25	Initiated	UBS	Buy	$30
Jun-11-25	Initiated	Leerink Partners	Underperform	$12
Mar-26-25	Upgrade	Citigroup	Neutral → Buy	$23 → $35
Mar-21-25	Initiated	Cantor Fitzgerald	Overweight
Mar-12-25	Initiated	Evercore ISI	Outperform	$30
Feb-28-25	Initiated	Goldman	Buy	$42
Jan-08-25	Initiated	Truist	Buy	$35
Dec-11-24	Initiated	Wells Fargo	Overweight	$30
Dec-06-24	Initiated	Jefferies	Buy	$31
Nov-04-24	Initiated	JMP Securities	Mkt Outperform	$32
Sep-27-24	Downgrade	Citigroup	Buy → Neutral	$19 → $23
Aug-12-24	Initiated	H.C. Wainwright	Buy	$16
May-07-24	Initiated	Citigroup	Buy	$7
Mar-26-24	Initiated	Stifel	Buy	$8
Jun-28-18	Downgrade	Janney	Buy → Neutral

Show Previous Ratings

Feb-06-26 08:00AM	China Biotech Lights Up. U.S. Stocks Prepare For A New Powerhouse. (Investor's Business Daily) +8.23%
Feb-05-26 07:22AM	FDA Accepts Summit Therapeutics' (SMMT) BLA For Ivonescimab In NSCLC With November 14 PDUFA Date Following Positive Phase III Data (Insider Monkey)
Jan-31-26 07:13PM	2 Stocks That Could Soar This Year (Motley Fool)
Jan-30-26 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.97%
10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
07:50AM	Loading…
07:50AM	Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings (Zacks)
Jan-29-26 12:28PM	FDA Accepts Summit's Lung Cancer Drug Application, Review Underway (Benzinga)
07:30AM	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy (Business Wire)
05:20AM	Moderna holds a garage sale; Roche defends obesity drug data (BioPharma Dive)
Jan-28-26 06:57AM	Encouraging Guidance on Clinical Program Makes Summit Therapeutics (SMMT) Look Attractive (Insider Monkey)
Jan-18-26 12:31PM	Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio? (Benzinga)
Jan-15-26 10:20PM	Akeso Confident of Cancer Drug's FDA Approval Odds (Bloomberg)
Jan-12-26 12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga) -13.41%
12:05PM	2 Biotech Stocks That Could Soar This Year (Motley Fool)
06:15AM	Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) (Business Wire)
06:00AM	Loading…
06:00AM	Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC (Business Wire)
Jan-09-26 08:16PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-26 07:30AM	Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) +7.00%
Jan-02-26 09:10AM	Cantor Fitzgerald Reaffirms Overweight Rating on Summit Therapeutics (SMMT) Before Key 2026 Catalyst (Insider Monkey)
Dec-29-25 01:53PM	Top Research Reports for Apple, Cisco & IBM (Zacks)
Dec-17-25 09:59AM	Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future? (Zacks)
Dec-11-25 07:44AM	Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development (Insider Monkey)
Dec-09-25 05:25PM	2 Stocks Up Over 600% in the Past 3 Years With More Room to Run (Motley Fool) -8.62% +5.41%
11:04AM	MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy? (Zacks)
Dec-05-25 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
01:25PM	Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? (Motley Fool)
Dec-03-25 04:44AM	Don't Buy Summit Therapeutics Until This Big Thing Happen (Motley Fool) +6.49%
Dec-02-25 07:00AM	2 Monster Stocks in the Making to Buy and Hold (Motley Fool)
Nov-27-25 09:45AM	AstraZeneca or Merck: Which Oncology Giant Has the Edge? (Zacks)
Nov-17-25 08:05AM	MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks) -5.99%
08:19PM	Loading…
Nov-10-25 08:19PM	Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial (Insider Monkey)
09:48AM	Will Keytruda Aid MRK's Growth in 2026 After a Subdued Q3? (Zacks)
Nov-07-25 09:00AM	Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China (Business Wire)
Nov-04-25 07:00AM	Summit Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Oct-31-25 07:07AM	Insiders Are Snapping Up These 2 Stocks and Analysts Like What They See (TipRanks)
07:00AM	Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 (Business Wire)
Oct-30-25 09:39PM	Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 (Insider Monkey)
Oct-28-25 06:43PM	Why Wall Street Is Backing These 3 Comeback Stocks (MarketBeat)
03:21PM	Insiders Are Buying These 3 Stocks Hand Over Fist (24/7 Wall St.)
12:37PM	Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know (Zacks)
Oct-27-25 05:51AM	1 Monster Stock in the Making to Buy and Hold (Motley Fool)
Oct-25-25 09:45AM	Insiders Are Scooping Up Shares of a Miner, a Driller, and a Biotech (24/7 Wall St.)
Oct-24-25 07:00PM	Summit Therapeutics: A Risky Bet in the Biotech Arena? (Motley Fool)
04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-21-25 01:41PM	SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments (Zacks) -6.46%
09:24AM	Company News for Oct 21, 2025 (Zacks)
05:53AM	Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab (Insider Monkey)
Oct-20-25 03:00PM	Summit Therapeutics Inc (SMMT) Q3 2025 Earnings Call Highlights: Promising Clinical ... (GuruFocus.com)
06:45AM	Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025 (Business Wire)
05:13AM	Summits dual-acting drug scores lung cancer win (BioPharma Dive)
Oct-19-25 10:30AM	Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China (Business Wire)
07:33AM	Tesla, Netflix set to report earnings as US-China trade fight turns 'unsustainable': What to watch this week (Yahoo Finance)
Oct-17-25 07:00AM	Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer (Business Wire)
Oct-15-25 07:00AM	Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 (Business Wire)
Oct-08-25 12:57AM	Where is Summit Therapeutics (SMMT) Headed According to Analysts? (Insider Monkey)
Oct-07-25 08:27AM	Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock? (Zacks)
Oct-05-25 09:45AM	1 Monster Stock in the Making to Buy and Hold (Motley Fool)
Oct-02-25 01:35AM	H.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab Milestones (Insider Monkey)
Oct-01-25 01:39PM	Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 (Insider Monkey)
Sep-24-25 04:30PM	Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.05%
07:00AM	HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 (Business Wire)
Sep-22-25 10:21AM	Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds? (Zacks)
Sep-18-25 11:25PM	Jim Cramer on Summit Therapeutics: "We're Going to Have to Move On" (Insider Monkey) +6.30%
10:41AM	Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China (Insider Monkey)
Sep-12-25 07:57PM	Lightning Round: Ring the register on Opendoor, don't be in a meme stock, says Jim Cramer (CNBC TV)
Sep-11-25 10:05AM	Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock? (Zacks) +5.65%
Sep-10-25 12:59AM	Guggenheim Initiates Summit Therapeutics (SMMT) With a Buy Rating (Insider Monkey) -6.48%
Sep-09-25 01:17PM	SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study (Zacks)
05:58AM	S&P Futures Tick Higher Ahead of U.S. Payrolls Revisions (Barchart)
05:51AM	Is Summit Therapeutics a Buy, Sell, or Hold Now? (Motley Fool)
Sep-08-25 06:12PM	Today's Moving Stocks: Planet Labs, EchoStar, Robinhood, Summit Therapeutics, BioNTech, CVS Health (TheStreet) -25.15%
04:08PM	Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch (Investor's Business Daily)
11:26AM	Stock Market Today: Stocks rise as investors embrace supersized cut chances (TheStreet)
09:33AM	Robinhood & Applovin, SpaceX & EchoStar, Summit Therapeutics (Yahoo Finance Video)
08:28AM	Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences (Benzinga)
07:53AM	New Summit data clouds approval pathway in lung cancer (BioPharma Dive)
Sep-07-25 03:30AM	Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC (Business Wire)
Sep-05-25 09:35AM	Apple upgraded, AMD downgraded: Wall Streets top analyst calls (TipRanks) +9.16%
Sep-04-25 09:33AM	Apple upgraded, AMD downgraded: Wall Street's top analyst calls (The Fly)
Sep-03-25 07:00AM	Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025 (Business Wire)
Aug-31-25 06:45AM	3 No-Brainer Stocks to Buy Right Now (Motley Fool)
12:10AM	H.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44 (Insider Monkey)
Aug-27-25 08:07AM	Stock Market Today: Stocks rise ahead of Nvidia's after hour earnings (TheStreet) -8.06%
Aug-19-25 09:06AM	Can Keytruda Sustain Merck's Growth Through the Rest of 2025? (Zacks)
Aug-18-25 11:43PM	Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism (Insider Monkey)
Aug-17-25 06:42AM	3 Fantastic Growth Stocks to Buy in August (Motley Fool)
Aug-14-25 07:00AM	Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 (Business Wire)
Aug-13-25 12:49PM	Summit Therapeutics (SMMT) Nosedives 9% on Dismal Earnings, Absence of Investor Call (Insider Monkey)
Aug-12-25 11:43AM	SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus (Zacks) -9.08%
Aug-11-25 05:03PM	Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025 (Business Wire)
09:17AM	Merck Stock Down 4% Since Q2 Results: How to Play the Stock (Zacks)
Jul-28-25 04:00AM	Could bispecifics unseat Keytruda from its oncology throne? (Pharma Voice)
Jul-25-25 08:27AM	Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results? (Zacks)
Jul-22-25 04:14AM	3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results (Motley Fool)
Jul-21-25 10:00AM	This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich (Motley Fool)
12:07AM	3 Monster Stocks in the Making to Buy Right Now (Motley Fool)
Jul-17-25 03:55PM	Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings (Insider Monkey)
Jul-14-25 11:08AM	Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits? (Zacks)
Jul-13-25 05:00PM	China Biotechs Stunning Advance Is Changing the Worlds Drug Pipeline (Bloomberg)
Jul-11-25 08:19AM	Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? (Zacks)

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xia Yu	Director	Oct 21 '25	Buy	18.74	533,617	9,999,983	32,057,147	Oct 23 09:06 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Oct 21 '25	Buy	18.74	26,680	499,983	76,680	Oct 23 04:08 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Oct 21 '25	Buy	18.74	26,680	499,983	76,680	Oct 23 04:06 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Sep 10 '25	Buy	17.68	333,394	5,894,406	556,088,090	Sep 11 07:36 PM
Zanganeh Mahkam	Co-Chief Executive Officer	Sep 11 '25	Buy	18.07	5,000	90,350	556,093,090	Sep 11 07:36 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Sep 10 '25	Buy	17.68	333,394	5,894,406	556,088,090	Sep 11 07:32 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	Sep 11 '25	Buy	18.07	5,000	90,350	556,093,090	Sep 11 07:32 PM
Zanganeh Mahkam	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 05:01 PM
DUGGAN ROBERT W	Co-Chief Executive Officer	May 30 '25	Option Exercise	2.64	74,545	196,799	555,754,696	Jun 02 04:55 PM

ILMN

Illumina Inc

SMMT

Summit Therapeutics Inc

Upgrade your FINVIZ experience